Skip to main content
OpenTrials
Completed

NCT Number: NCT07419074

Hypoglycemic Potential of Garcinia Cambogia (Garcinia Gummi-gutta (L.) N.Robson) Rind Powder Among Pre-diebetic Obese Patients

Garcinia cambogia, rich in hydroxycitric acid (HCA), has been suggested to promote weight loss and improve metabolic parameters. Evidence regarding its efficacy in pre-diabetic obese adults remains limited.

Objective: To evaluate the effects of Garcinia cambogia rind powder supplementation on anthropometric, glycemic, lipid, hepatic, and renal parameters in pre-diabetic obese adults.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Lipid Profile Adenoma Adenoma, Liver Cell Body Weight Digestive System Diseases Digestive System Neoplasms Glucose Intolerance Glucose Metabolism Disorders Hyperglycemia Liver Diseases Liver Neoplasms Metabolic Diseases Neoplasms Neoplasms by Histologic Type Neoplasms by Site Neoplasms, Glandular and Epithelial Nutrition Disorders Nutritional and Metabolic Diseases Obesity Overnutrition Overweight Pathological Conditions, Signs and Symptoms Signs and Symptoms

Age range

30 year–60 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

Sana Noreen

Lahore, 54000, Pakistan

About this study

The observed effects are likely mediated by HCA, which inhibits ATP-citrate lyase, reducing de novo lipogenesis, enhancing glucose utilization, and modulating adipokines and oxidative stress.

Conclusion: Garcinia cambogia rind powder supplementation exerts dose-dependent metabolic benefits in pre-diabetic obese adults, improving anthropometric, glycemic, lipid, hepatic, and renal parameters without adverse effects. It may serve as a complementary intervention alongside lifestyle modification for the management of obesity and pre-diabetes.

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Participants of both genders were included if they were aged 30-60 years,
  • body mass index (BMI) ≥30 kg/m²,
  • Individuals with HbA1c levels ranging from 5.7% to 10% were selected, .indicating pre-diabetic to diabetic status. Participants were required to have a .body mass index (BMI) of 25 kg/m² or higher

Exclusion criteria

  • Participants who were diagnosed with type 1, pregnant or lactating,
  • chronic liver, kidney, or cardiovascular disease,
  • history of hepatotoxicity or gastrointestinal disorders,
  • using weight-loss supplements, steroids, or lipid-lowering drugs, or had a known allergy to Garcinia cambogia

Treatment and study plan

Garcinia cambogia rind powder

Dietary Supplement

Once a day

Primary outcomes

  1. Weight

    Time frame: 12 weeks

Secondary outcomes

  1. Lipid profile

    Time frame: 12 weeks

  2. fasting glucose

    Time frame: 12 weeks

Sponsors and collaborators

Lead sponsor

University of Lahore

Other

Registry information

Important dates

Study start
2025
Primary completion
2025
Study completion
2026
First posted
Feb 18, 2026
Registry last updated
Feb 18, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.